Advertisement

ADVERTISEMENT

outcomes research

News
Impact of Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer
06/01/2020
On the first day of the American Society of Clinical Oncology (ASCO) Annual Meeting (May 30, 2020), Helen MacKay, MBChB, BSc, MRCP, MD, department of medicine, University of Toronto, provided the context and...
On the first day of the American Society of Clinical Oncology (ASCO) Annual Meeting (May 30, 2020), Helen MacKay, MBChB, BSc, MRCP, MD, department of medicine, University of Toronto, provided the context and...
On the...
06/01/2020
Journal of Clinical Pathways
News
Long-Term Follow-Up Data Supports Frontline Treatment Option for Older AML Patients
05/21/2020
Venetoclax plus low-dose cytarabine offers a clinically meaningful improvement in survival compared with placebo plus low-dose cytarabine in previously untreated older patients with acute myeloid leukemia (AML),...
Venetoclax plus low-dose cytarabine offers a clinically meaningful improvement in survival compared with placebo plus low-dose cytarabine in previously untreated older patients with acute myeloid leukemia (AML),...
...
05/21/2020
Journal of Clinical Pathways
News
Comparative Effectiveness of Monotherapies for Relapsed, Refractory Hodgkin Lymphoma
05/14/2020
In patients with relapsed or refractory classic Hodgkin lymphoma, pembrolizumab may be superior to brentuximab vedotin and provide statistically significant and clinically meaningful improvement in PFS across all subgroups.
In patients with relapsed or refractory classic Hodgkin lymphoma, pembrolizumab may be superior to brentuximab vedotin and provide statistically significant and clinically meaningful improvement in PFS across all subgroups.
In patients with relapsed or...
05/14/2020
Journal of Clinical Pathways
News
Breast Cancer Survival Outcomes After Mastectomy Versus Breast-Conserving Surgery
08/22/2017
JCP Editors
A recent comparative effectiveness study examined long-term survival outcomes for patients with multiple stages of breast cancer after undergoing either mastectomy or breast-conserving surgery, published in the...
A recent comparative effectiveness study examined long-term survival outcomes for patients with multiple stages of breast cancer after undergoing either mastectomy or breast-conserving surgery, published in the...
A...
08/22/2017
Journal of Clinical Pathways
Research in Review
Aggressive Local Therapy Improves Outcomes in Patients With Head and Neck Cancer
08/18/2017
JCP Editors
A recent study uncovered the benefits of adding high-intensity local treatment to systemic therapy for head and neck squamous cell carcinoma, published in Cancer (online August 17, 2017;...
A recent study uncovered the benefits of adding high-intensity local treatment to systemic therapy for head and neck squamous cell carcinoma, published in Cancer (online August 17, 2017;...
A...
08/18/2017
Journal of Clinical Pathways
Research in Review
Comparative Effectiveness Study Examines Treatment Options for DLBCL
08/18/2017
JCP Editors
A recent study compared the treatment effects and adverse events of first-line chemotherapy regimens in patients with treatment-naïve diffuse large B-cell lymphoma (DLBCL). Rituximab plus cyclophosphamide,...
A recent study compared the treatment effects and adverse events of first-line chemotherapy regimens in patients with treatment-naïve diffuse large B-cell lymphoma (DLBCL). Rituximab plus cyclophosphamide,...
A...
08/18/2017
Journal of Clinical Pathways
Author Insights
Cost-Effective Alternative Identified for Autologous Stem Cell Mobilization in Multiple Myeloma
08/14/2017
Pavan Bhamidipati, MBBS, MD
In a randomized, open-label study, we discovered that tbo-filgrastim (Granix) can be used in the place of filgrastim (Neupogen) for autologous stem cell mobilization for multiple myeloma and non-Hodgkin’s lymphoma...
In a randomized, open-label study, we discovered that tbo-filgrastim (Granix) can be used in the place of filgrastim (Neupogen) for autologous stem cell mobilization for multiple myeloma and non-Hodgkin’s lymphoma...
In a...
08/14/2017
Journal of Clinical Pathways
Research in Review
Predicting Survival, Treatment Response in Patients With Follicular Lymphoma
08/14/2017
JCP Editors
A recent study suggests a variable that should be used as a standard outcome measure for clinical trials of patients with follicular lymphoma, published in the British Journal of Hematology (online August 7, 2017;...
A recent study suggests a variable that should be used as a standard outcome measure for clinical trials of patients with follicular lymphoma, published in the British Journal of Hematology (online August 7, 2017;...
A...
08/14/2017
Journal of Clinical Pathways
Research in Review
Impact of Vitamin D Deficiency on Relapse in Patients With Myeloid Malignancies
08/10/2017
JCP Editors
Patients with myeloid malignancies who have vitamin D deficiency before undergoing allogeneic stem cell transplantation (alloSCT) are at a higher risk of relapse, according to recent research published in the Journal...
Patients with myeloid malignancies who have vitamin D deficiency before undergoing allogeneic stem cell transplantation (alloSCT) are at a higher risk of relapse, according to recent research published in the Journal...
...
08/10/2017
Journal of Clinical Pathways
Research in Review
Double Dosage of ALK Inhibitor Improves Outcomes in NSCLC
08/09/2017
JCP Editors
Increasing the standard dose of an anaplastic lymphoma kinase (ALK) inhibitor for the treatment of non-small cell lung cancer (NSCLC) improves objective response rates (ORR) by 9% with limited additional toxicity,...
Increasing the standard dose of an anaplastic lymphoma kinase (ALK) inhibitor for the treatment of non-small cell lung cancer (NSCLC) improves objective response rates (ORR) by 9% with limited additional toxicity,...
...
08/09/2017
Journal of Clinical Pathways

Advertisement

Advertisement

Advertisement

Advertisement

Upcoming Events

Psych Congress Regionals
July 18 ⁠–⁠ July 19
Advances in Inflammatory Bowel Disease Regionals
July 19 ⁠–⁠ July 20
July 24 ⁠–⁠ July 26
APP Institute Inflammatory Bowel Disease
July 26 ⁠–⁠ July 27
July 27 ⁠–⁠ July 28
July 27 ⁠–⁠ July 28
Psych Congress Regionals
August 8 ⁠–⁠ August 9
August 14 ⁠–⁠ August 17
August 16 ⁠–⁠ August 18
APP Institute Dermatology
August 16 ⁠–⁠ August 17
See Full Calendar

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Privacy Policy Terms of Use